In the November issue of MedNous, Dr Paula Salmikangas, Dr Björn Carlsson and Dr Steffen Thirstrup address the risks and challenges of gene editing.
In recent years, gene editing technologies have moved from non-clinical tests into first in human clinical studies. Although it is still in the early days, there are currently a substantial number of ongoing early-stage clinical trials as well as encouraging single case reports demonstrating proof-of-concept.
In this article, Drs Paula Salmikangas, Björn Carlsson and Steffen Thirstrup examine the most common techniques to change the genome, the risk of tumour-formation and off-target editing